GH Research Shares Rise Ahead of Release of Clinical-Trial Results

Dow Jones

02-01

By Connor Hart

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression.

The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year.

The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001.

In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment.

The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 31, 2025 17:43 ET (22:43 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2508913784"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508913784\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2508913784?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-01 06:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508913784","market":"sg","top_or_hot":-1,"title":"GH Research Shares Rise Ahead of Release of Clinical-Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. \n</p>\n<p>\n  The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year. \n</p>\n<p>\n  The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001. \n</p>\n<p>\n  In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment. \n</p>\n<p>\n  The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 31, 2025 17:43 ET (22:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research Shares Rise Ahead of Release of Clinical-Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research Shares Rise Ahead of Release of Clinical-Trial Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-02-01 06:43</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. \n</p>\n<p>\n  The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year. \n</p>\n<p>\n  The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001. \n</p>\n<p>\n  In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment. \n</p>\n<p>\n  The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 31, 2025 17:43 ET (22:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2508913784","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508913784","pubTimestamp":1738363380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression.The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year.The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001.In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment.The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","GH":"Guardant Health Inc.","BK4539":"次新股","BK4007":"制药","GHRS":"GH Research PLC","BK4196":"保健护理服务","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4585":"ETF&股票定投概念"},"translate_title":"GH Research股价在临床试验结果发布前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1,"GHRS":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. \n\n\n  The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year. \n\n\n  The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001. \n\n\n  In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment. \n\n\n  The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 31, 2025 17:43 ET (22:43 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}